During recent decades, the emergence of pathogenic fungi has posed an increasing public
health threat, particularly given the limited number of antifungal drugs available to treat …

Invasive Candida infections remain an important cause of morbidity and mortality, especially
in hospitalized and immunocompromised or critically ill patients. A limited number of …

The use of antifungal drugs in the therapy of fungal diseases can lead to the development of
antifungal resistance. Resistance has been described for virtually all antifungal agents in …

Fungal infections, such as candidiasis caused by Candida, pose a problem of growing
medical concern. In developed countries, the incidence of Candida infections is increasing …

Candida auris is an emerging multidrug-resistant yeast first described in 2009 that has since
caused healthcare-associated outbreaks of severe human infections around the world. In …

Fungal pathogens are a growing threat to public health. As human immunodeficiency
becomes increasingly common, fungal infections are becoming more prevalent. The use of …

The emergence of new fungal pathogens makes the development of new antifungal drugs a
medical imperative that in recent years motivates the talents of numerous investigators …

Fungal infections are on the rise, driven by a growing population at risk and climate change.
Currently available antifungals include only five classes, and their utility and efficacy in …

Candida (Clavispora) lusitaniae is a rare, emerging non-albicans Candida species that can
cause life-threatening invasive infections, spread within hospital settings, and rapidly …

Clustered regularly interspaced short palindromic repeat (CRISPR)-Cas9 genome
modification systems have greatly facilitated the genetic analysis of fungal pathogens. In …